Myriad Genetics Reports Q4/FY25 Results with $319M Impairment, Reaffirms 2026 Guidance
MYGN sits 22% above its 52-week low of $3.76.
Summary
Myriad Genetics reported Q4 and full-year 2025 financial results, including a significant $319.4 million goodwill and long-lived asset impairment charge for the year, while reaffirming its full-year 2026 financial guidance.
Key Events · Earnings and Guidance · MYGN
-
Q4 and Full-Year 2025 Financial Results
Fourth quarter 2025 revenue was $209.8 million, consistent year-over-year. Full-year 2025 revenue was $824.5 million, a 2% decrease year-over-year (or 2% growth excluding specific headwinds). GAAP net loss for Q4 2025 was $7.9 million, with adjusted EPS of $0.04.
-
Significant Impairment Charge
The company recorded a substantial $319.4 million goodwill and long-lived asset impairment charge for the full year 2025, primarily associated with its Mental Health and Women's Health reporting units and asset groups.
-
Reaffirmed 2026 Financial Guidance
Myriad Genetics reiterated its full-year 2026 revenue guidance of $860-$880 million and adjusted EBITDA guidance of $37-$49 million.
-
Operational Highlights and New Test Launches
The company reported positive test volume growth in Hereditary cancer (9%), Prolaris (12%), and GeneSight (9%) for Q4 2025. It also announced plans for three significant new test launches in 2026, including Precise MRD, an AI-enabled Prolaris test, and FirstGene.
Analysis · MYGN · Life Sciences
The filing reveals a substantial $319.4 million goodwill and long-lived asset impairment charge for the full year 2025, primarily impacting the Mental Health and Women's Health reporting units. This massive write-down, representing a significant portion of the company's asset base, indicates a material reassessment of asset values and raises concerns about the performance and outlook of these key business segments. While the company reported some positive operational momentum with volume growth in hereditary cancer, Prolaris, and GeneSight tests, and reiterated its 2026 financial guidance, the impairment charge overshadows these positives. Investors should scrutinize the underlying reasons for the impairment and its potential long-term implications for the company's strategic direction and profitability, despite the planned new test launches.
At the time of this filing, MYGN was trading at $4.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $408.3M. The 52-week trading range was $3.76 to $15.18. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.